![]() ![]() This should potentially translate into higher vaccine demand. Moreover, Covid-19 cases are on the rise once again in the U.S., and businesses and other institutions are also increasingly mandating vaccinations. Firstly, the company’s vaccine deal with Australia has apparently been delayed due to issues related to manufacturing and regulatory authorization. There are likely a couple of factors driving the decline. The stock is also down by almost 16% over the last month (21 trading days). Novavax (NASDAQ: NVAX) stock has declined by almost 12% over the last week (five trading days), compared to the S&P 500 which has remained roughly flat over the same period. This could also eventually bode well for companies such as Novavax, once it has the relevant approvals. ![]() could have a Covid-19 vaccine mandate for children returning to school. Moreover, there is a possibility that the U.S. Novavax’s highly effective and affordable shot, which has seen relatively few side effects could act as a booster shot for people who have previously been inoculated with other vaccines. People also appear to be interested in these shots, with a Reuters/Ipsos poll finding that 76% of vaccinated Americans want a booster. will offer booster shots to all Americans starting from September 20th. The seven-day average of Covid-19 cases stood at about 160,000 as of August end, about double the number from just about a month ago and there appears to be growing consensus that booster doses of Covid-19 vaccines are required to strengthen immunity and tackle new variants. have been surging, driven by the highly infectious delta variant of the virus. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |